Skip to content

Author

Katherine A. Janeway

We have 5 of 54 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N)

Abstract Background This is a phase II subprotocol of the National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial evaluating selpercatinib, a RET inhibitor, in children and young adults aged 1-21 years with relapsed or refractory soli...

Andrea T. Franson, Samara L. Potter, P. Williams et al. · 0 citations
Open access Sep 2026

Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study.

PURPOSE Identification of discrete risk groups remains a high priority for patients with Ewing sarcoma (EWS). We sought to prospectively validate circulating tumor DNA (ctDNA) as a prognostic factor and develop clinical-molecular risk groups. METHODS We conducted a prospective investigator-initiated biology study for...

D. Shulman, Kelly S. Klega, Nan Chen et al. · 0 citations
Aug 2025

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have large...

Anna Borgenvik, Sean A. Misek, Daniel Christen et al. · 1 citation
Sep 2026

Abstract IA02: Single-cell regulatory network analysis of therapy-associated cell state remodeling to inform combination strategies in osteosarcoma

A single-cell regulatory network analysis of therapy-associated cell state remodeling to inform combination strategies in osteosarcoma and single-cell profiling reveals drug effects missed by bulk efficacy measures is extended.

J. Pavisic, Chelsey M. Burke, Dao-Qi You et al. · 0 citations
Open access Sep 2026

Clustered structural variant hotspots enable oncogenic addiction and plasticity in osteosarcoma

Across 236 whole-genome sequencing osteosarcoma samples, five genomic hotspots of clustered structural variation collectively altered in 58% of tumors were uncovered, and localized transcriptional dysregulation at hotspot event loci was found, linking these structural alterations to a less differentiated cell state.

Shreya Raman, Thorsten Kaltenbacher, David Merrell et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.